RESUMO
The research progress of puerarin and its derivatives in anti-inflammatory and anti-gout activities was reviewed in this paper. Puerarin possesses anti-inflammatory activity by affecting immunocyte, inflammation cytokines and signaling pathway. Puerarin also has anti-gout activity through inhibition of xanthine oxidase, promoting the excretion of uric acid to reduce serum uric acid level. Although its ability in reducing uric acid level was lower than that of allopurinol in clinical application, puerarin can also enhance the total antioxidant and free radical scavenging with stronger anti-inflammatory effect, so it will be a promising research direction to find new drugs with better anti-gout activity and less side effects by modifying the chemical structure of puerarin.
RESUMO
Objective:To investigate the anti-gout capsule ( AGC) effect on acute gouty arthritis ( AGA) rat tumor necrosis factor-α(TNF-α)level.Methods: Selected 60 SD rats,were randomly divided into normal group,model group,colchicine group(0.8 mg/kg),AGC low dose group (0.3 g/kg) and AGC high dose group (1.2 g/kg),12 rats in each group,detected each group articular cartilage,serum and synovial fluid TNF-αcontent,observed rats ankle swelling.Results: The model group 24 h,48 h gait behavior scores were(2.57±0.43)point and(2.11±0.50)point,significantly higher than other groups (P0.05 );AGC high dose group and low dose group articular cartilage TNF-αexpression significantly decreased than model group ( P<0.05).The model group serum and synovial fluid TNF-αcontent were significantly higher than the normal group (P<0.05);colchicine group,AGC low dose group and AGC high dose group serum and synovial fluid TNF-αcontent reduced compared with the model group (P<0.05);AGC low dose group and AGC high dose group serum TNF-αwere(0.81±0.27)ng/ml and(0.79±0.31)ng/ml,lower than the colchicines group ( P<0.05 ).Conclusion:AGC can significantly improve the joint symptoms of AGA rats ,decrease AGA rats articular cartilage tissue ,serum and synovial fluid TNF-αlevel.
RESUMO
We selected Pleurotus ostreatus from among several edible mushrooms because it has high anti-gout xanthine oxidase (XOD) inhibitory activity. The maximal amount of XOD inhibitor was extracted when the Pleurotus ostreatus fruiting body was treated with distilled water at 40degrees C for 48 hr. The XOD inhibitor thus obtained was purified by Sephadex G-50 gel permeation chromatography, ultrafiltration, C18 solid phase extraction chromatography and reverse-phase high-performance liquid chromatography with 3% of solid yield, and its XOD inhibitory activity was 0.9 mg/mL of IC50. The purified XOD inhibitor was a tripeptide with the amino acid sequence phenylalanine-cysteine-histidine and a molecular weight of 441.3 Da. The XOD inhibitor-containing ultrafiltrates from Pleurotus ostreatus demonstrated dose-dependent anti-gout effects in a Sprague-Dawley rat model of potassium oxonate-induced gout, as shown by decreased serum urated levels at doses of 500 and 1,000 mg/kg, although the effect was not as great as that achieved with the commercial anti-gout agent, allopurinol when administered at a dose of 50 mg/kg.